A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Alferminogene-tadenovec (Primary)
- Indications Angina pectoris; Myocardial infarction
- Focus Therapeutic Use
- Acronyms AFFIRM
- Sponsors Angionetics
- 20 Mar 2017 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
- 20 Mar 2017 Planned primary completion date changed from 1 May 2019 to 1 Sep 2019.
- 20 Mar 2017 Planned initiation date changed from 1 Apr 2017 to 1 Sep 2017.